BIOLASE Issued New Patent for Cleaning and Disinfecting Root Canals
14 September 2011 - 11:00PM
Marketwired
BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental
laser manufacturer and distributor, today announced that the U.S.
Patent and Trademark Office has issued BIOLASE a new patent, number
8,002,544, titled "Fluid Controllable Laser Endodontic Cleaning and
Disinfecting System."
The new patent is the 10th issued patent in this field and
significantly strengthens the Company's intellectual property (IP).
It relates to the use of an endodontic probe to perform
disinfection procedures within the root canal. The endodontic probe
can be loaded with biologically-active particles, cleaning
particles, biologically-active agents or cleaning agents for
delivery to the target tissues. It also includes an adjustable
channel-depth indicator, a practical way to measure and control the
depth of the probe for root canal procedures as well as other
features to further improve cleaning/disinfection.
According to multiple sources, 30 to 50 million root canal
procedures are performed in the US per year with the drill and
metal endodontic files. Despite various improvements in
conventional therapy, failure rates continue to range between 10
and 15 percent requiring more than three million additional
advanced dental procedures. Primary causes of this high rate of
failures include under filled or missed root canals, tooth
fractures, and inadequate cleaning which result in leakage,
bacterial contamination or re-contamination. Recent studies have
shown that improving the effectiveness of cleaning and disinfection
at the apex of the tooth doubled the chance for a successful
clinical outcome while every millimeter missed reduced the success
rate by 12 percent.
Researchers have also found that bacteria and toxins from root
canals are capable of entering the bloodstream and traveling to any
point in the body generating disease in tissue or organs. A link
between root canal treatment and diabetes, arthritis, Multiple
Sclerosis, Lupus and host of auto immune diseases has been reported
by the non-profit research foundation Toxic Element Research
foundation (TERF).
Federico Pignatelli, Chairman and CEO, commented, "Our current
Endolaseā¢ Root Canal Therapy System utilizing our Waterlase
Er,Cr:YSGG technology with our patented radial firing tips and
clinically proven technique has shown the ability to reduce root
canal bacterial levels by 99.7 percent. We believe that elements
included in this new patent in combination with our other related
IP may allow us to finally achieve the goal of every company in the
industry -- complete root canal sterilization.
"The substantial reduction in root canal treatment time proposed
by the new endodontic technique in addition to the approximately 3X
improvement documented in the scientific clinical literature with
our technology over the current standard, should attract even more
General Practitioners and Endodontists that have not yet adopted
laser endodontic therapy," continued Pignatelli. "We have a number
of doctors who are providing their patients with the confidence
that they will not be the 1 in 10 who will require an additional
expensive dental procedure, usually from an endodontic
specialist."
About BIOLASE Technology, Inc. BIOLASE
Technology, Inc., the World's leading Dental Laser company, is a
medical technology company that develops, manufactures and markets
dental lasers and also distributes and markets dental imaging
equipment, products that are focused on technologies that advance
the practice of dentistry and medicine. The Company's laser
products incorporate patented and patent pending technologies
designed to provide clinically superior performance with less pain
and faster recovery times. Its imaging products provide
cutting-edge technology at competitive prices to deliver the best
results for dentists and patients. BIOLASE's principal products are
dental laser systems that perform a broad range of dental
procedures, including cosmetic and complex surgical applications,
and a full line of dental imaging equipment. Other products under
development address ophthalmology and other medical and consumer
markets.
For updates and information on laser and Waterlase dentistry,
find BIOLASE at http://www.biolase.com, Twitter at
http://twitter.com/GoWaterlase, and YouTube at
http://www.youtube.com/user/Rossca08.
This press release may contain forward-looking statements within
the meaning of safe harbor provided by the Securities Reform Act of
1995 that are based on the current expectations and estimates by
our management. These forward-looking statements can be identified
through the use of words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates," "may,"
"will," and variations of these words or similar expressions.
Forward-looking statements are based on management's current,
preliminary expectations and are subject to risks, uncertainties
and other factors which may cause the Company's actual results to
differ materially from the statements contained herein, and are
described in the Company's reports it files with the Securities and
Exchange Commission, including its annual and quarterly reports. No
undue reliance should be placed on forward-looking statements. Such
information is subject to change, and we undertake no obligation to
update such statements.
For further information, please contact: Jill Bertotti Allen
& Caron +1-949-474-4300
Biolase (NASDAQ:BLTI)
Historical Stock Chart
From May 2024 to Jun 2024
Biolase (NASDAQ:BLTI)
Historical Stock Chart
From Jun 2023 to Jun 2024